All News

Investigators plan to submit a communication application to seek marketing approval in China for ARX788 as therapy for HER2-positive advanced or metastatic breast cancer.

Investigators are assessing FORE8394, which received orphan drug designation from the FDA, in primary brain and central nervous system malignancies in the phase 2 FORTE trial.

Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.

Data from the phase 2 INNATE trial indicate that pimivalimab plus JTX-8064 also appears to be well tolerated in patients with platinum-resistant ovarian cancer.

Bria-IMT plus retifanlimab continues to show positive clinical outcomes in a small cohort of patients with advanced, metastatic breast cancer, according to data from a phase 1/2 trial.

Enzalutamide plus leuprolide appears to improve metastases-free survival vs placebo plus leuprolide in patients with non-metastatic hormone-sensitive prostate cancer.

The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.

The phase 3 LIMBER-304 trial examining parsaclisib with ruxolitinib vs matched placebo will be discontinued after an interim analysis concluded it would likely miss the primary end point.

Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.

New findings from the phase 3 ADAURA trial “provide powerful evidence” of osimertinib’s potential to extend the lives of patients with early-stage, EGFR-mutant non–small cell lung cancer, according to an expert from Yale Cancer Center.

Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.

A panel of experts reviews how the recent approval of teclistamab, a bispecific antibody, has changed the treatment landscape for patients with multiple myeloma.

Investigators indicate that although avoiding efficient mantle cell lymphoma treatment due to late effects may seem okay, most long-term health care needs are disease related in patients up to 70 years.

Results from the phase 2 CDRB436G2201 trial lead to the approval of dabrafenib plus trametinib in patients with low-grade glioma and a BRAF V600E mutation who require systemic therapy.

Use of a kit that prepares for gallium Ga 68 gozetotide injection in the phase 3 VISION study affirms its ability to identify patients who are suitable to receive PSMA-based radioligand for metastatic prostate cancer.

Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.

Findings from a confirmatory factor analysis appear to validate the structure of the Quality of Life in Myelodysplasia Scale in myelodysplastic syndromes.

National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.

Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.

Vorasidenib monotherapy appears to improve clinical outcomes among patients with IDH-mutant low-grade glioma, meeting 2 end points in the phase 3 INDIGO trial.

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

EP0042 shows promising early clinical efficacy in patients with pretreated acute myeloid leukemia, according to investigators.

Anthony D’Amico, MD, PhD, reviewed current practices and unanswered questions surrounding radiotherapy in the realm of prostate cancer.

Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.

Matthew Dallos, MD, discusses current challenges in the treatment of castration-resistant prostate cancer and the potential of antibody-drug conjugates in this disease space.

The addition of bortezomib to dexamethasone plus rituximab and cyclophosphamide appears to improve progression-free survival among those with Waldenström Macroglobulinemia.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.

Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.

Nirogacestat may be a noteworthy therapeutic advance for patients with desmoid tumors, according to an expert from Memorial Sloan Kettering Cancer Center.

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.